Sugi Predict

Sugi Predict / Compounds / SCHEMBL2901294

SCHEMBL2901294

SCHEMBL2901294

C[C@H]1CN(C(=O)O)CCN1C

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CHRM1 P11229 2/20 0.49
▸ CNR1 P21554 4/20 0.34
▸ CNR2 P34972 2/20 0.34
▸ GSK3B P49841 2/20 0.34
▸ DYRK1A Q13627 2/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ P2RX7 Q99572 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ LMNA P02545 2/20 0.32
▸ ALOX15 P16050 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ HTT P42858 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2908533 1.00 CHRM1 (0.49) CHRM1CNR1CNR2GSK3BDYRK1A
SCHEMBL2379763 1.00 CHRM1 (0.49) CHRM1CNR1CNR2GSK3BDYRK1A
SCHEMBL8038153 0.98 CHRM1 (0.48) CHRM1CNR1CNR2GSK3BDYRK1A
Hydrochloric Acid SCHEMBL28577068 0.98 CHRM1 (0.48) CHRM1CNR1CNR2GSK3BDYRK1A
Hydrochloric Acid SCHEMBL28577066 0.98 CHRM1 (0.48) CHRM1CNR1CNR2GSK3BDYRK1A
Hydrochloric Acid SCHEMBL28915471 0.98 CHRM1 (0.48) CHRM1CNR1CNR2GSK3BDYRK1A
SCHEMBL20434091 0.83 CYP1A2 (0.48) CHRM1GSK3BDYRK1ACYP1A2TDP1
SCHEMBL15431899 0.83 CYP1A2 (0.48) CHRM1GSK3BDYRK1ACYP1A2TDP1
SCHEMBL17625631 0.83 CYP1A2 (0.48) CHRM1GSK3BDYRK1ACYP1A2TDP1
SCHEMBL4492046 0.81 CHRM1 (0.44) CHRM1CNR1CNR2GSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11679107-B2 Certain aryl pladienolide compounds and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-06-20 — — US claimed
US-20210177837-A1 CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-06-17 — — US claimed
EP-3774760-A1 PLADIENOLIDE DERIVATIVES AS SPLICEOSOME TARGETING AGENTS FOR TREATING CANCER Eisai R&D Management Co., Ltd. (JP) 2021-02-17 — — EP claimed
WO-2019200100-A1 PLADIENOLIDE DERIVATIVES AS SPLICEOSOME TARGETING AGENTS FOR TREATING CANCER COOK ANDREW (US) 2019-10-17 — — WO claimed
US-20230301990-A1 CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-09-28 — — US disclosed
US-20230219926-A1 SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING FACIT INC. (CA) 2023-07-13 — — US disclosed
US-11679107-B2 Certain aryl pladienolide compounds and methods of use EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-06-20 — — US disclosed
CN-112996784-B Indole derivatives and their use in medicine 北京越之康泰生物医药科技有限公司 2023-05-30 — — CN disclosed
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 — — US disclosed
EP-4144735-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Array Biopharma, Inc. (US) 2023-03-08 — — EP disclosed
EP-3423451-B1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING PROPELLON THERAPEUTICS INC (CA) 2022-08-17 — — EP disclosed
CN-109195965-B Inhibitors of WDR5 protein-protein binding 普罗佩纶治疗公司 2022-07-26 — — CN disclosed
EP-2217226-B1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2015-07-22 — — EP disclosed
US-20130045962-A1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC 2013-02-21 — — US disclosed
CN-101917981-A Peptide deformylase inhibitors SMITHKLINE BEECHAM CORP 2010-12-15 — — CN disclosed
EP-2217226-A1 PEPTIDE DEFORMYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-08-18 — — EP disclosed
US-20090306066-A1 PEPTIDE DEFORMYLASE INHIBITORS GLAXOSMITHKLINE LLC 2009-12-10 — — US disclosed
WO-2009061879-A1 PEPTIDE DEFORMYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-05-14 — — WO disclosed
EP-1501805-A1 SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2005-02-02 — — EP disclosed
WO-2003095430-A1 SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-11-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11679107-B2 Certain aryl pladienolide compounds and methods of use PLAAT5, PLAAT3, SNRPE CHRM1 4861/4885CNR1 3632/4885CNR2 3548/4885
US-20230301990-A1 CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE PLAAT5, PLAAT3, PLAAT4 CHRM1 4863/4885CNR1 3897/4885CNR2 3877/4885
US-20130045962-A1 PEPTIDE DEFORMYLASE INHIBITORS PDF, DPEP1, DHPS CHRM1 4857/4885CNR1 4795/4885CNR2 4814/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 CHRM1 2035/4885CNR1 3827/4885CNR2 4423/4885
US-20210177837-A1 CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE PLAAT5, PLAAT3, PLAAT4 CHRM1 4860/4885CNR1 3611/4885CNR2 3576/4885
US-20090306066-A1 PEPTIDE DEFORMYLASE INHIBITORS PDF, DHPS, PADI3 CHRM1 4835/4885CNR1 4747/4885CNR2 4773/4885
US-20230219926-A1 SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING WDR5, WDR82, WDR1 CHRM1 4761/4885CNR1 2459/4885CNR2 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.